PHAR (Pharming) שולי רווח גולמי

Active growth in demand for orphan drugs drives the gross income dynamics within revenue, where the value of 82.80 represents the latest figure for Pharming Group N.V. (PHAR). The business stability of Pharming Group N.V. (PHAR) is ensured by the critical nature of medications that remain independent of economic cycles. Meanwhile, the European management system guarantees strict risk control and transparency in global distribution, minimizing the likelihood of sharp margin contractions.
פילוחים אנליטיים ודוחות נתונים של חברת Pharming Group (PHAR)

To assess the long-term sustainability of Pharming Group N.V. (PHAR), investors analyze the gross margin, calculated as the remaining revenue after deducting direct production costs, which reflects the efficiency of cost-of-goods-sold management. The trend in the gross margin share confirms high business profitability, driven by stable demand for biotechnology and the isolation of Pharming Group N.V. operational processes from global macroeconomic fluctuations.